Developer docs
API playgroundTry for free, no card

Search company profiles

Hemostemix

Full company profile

uuid0000no9

Namestring
Hemostemix
Legal namestring
Hemostemix Inc.
Websiteurl
hemostemix.com
Company typeenum
Public
Founded yearint
2003
Descriptiontext

Hemostemix Inc. is a clinical-stage biotechnology company headquartered in Calgary, Alberta, Canada, founded in 2003 (previously known as TheraVitae Inc.) and listed on the TSX Venture Exchange (HEM), OTCQB (HMTXF), and Frankfurt Stock Exchange (2VF0). The company develops autologous stem cell therapies for ischemic conditions that lack effective conventional treatments, with its lead product ACP-01 (marketed as VesCell) consisting of CD34+ angiogenic cell precursors isolated from a patient's own blood via peripheral venipuncture, expanded over seven days in a cGMP-compliant Montreal manufacturing facility, and administered via outpatient intramuscular injection. The platform is protected by over 90 patents across five patent families and has been evaluated across seven clinical studies involving 498 subjects, with results published in 11 peer-reviewed journals including 0% serious adverse events and 83% limb salvage in CLTI cohorts followed to 4.5 years.

The company pursues a basket IND strategy targeting six ischemic indications — peripheral arterial disease (PAD), chronic limb-threatening ischemia (CLTI), ischemic cardiomyopathy, congestive heart failure, refractory angina, and vascular dementia — all sharing microvascular perfusion insufficiency as a common mechanism. ACP-01's collection method (blood draw only) is differentiated from competitors requiring bone marrow aspiration or liposuction. The company operates a sales-led, direct-to-consumer model selling treatments at $50,000 each — well below the $300,000-$500,000 benchmarks of approved cell and gene therapies in adjacent indications. Commercial access exists in Florida under Senate Bill 1768 (Right-to-Try), The Bahamas under LARTA, and Canada through clinical frameworks, with the FDA accepting real-world evidence under IRB oversight. The company completed an FDA Pre-IND meeting in January 2026 for a basket clinical trial protocol.

Revenue mechanics rely on per-treatment cash sales plus Therapy Convertible Debentures tied to treatment revenue. Operations are funded primarily through repeated small private placements (multiple rounds in 2025-2026 totaling several million USD), insider participation by directors Mr. Lacey and Mr. Swanberg, and grant funding (e.g., $250K from McGill University Health Centre Foundation). Recent strategic moves include the appointment of Chief Commercial Officer Croom Lawrence with revenue share, a binding LOI to acquire two Dominican Republic cardiology practices in November 2025, a PreCerv Inc. spin-off housing the NCP-01 neuronal cell precursor technology, and pursuit of First Nations-led treatment center partnerships via Dr. York Hsiang.

Short descriptiontext

Hemostemix is a publicly traded clinical-stage biotechnology company developing ACP-01 (VesCell), an autologous CD34+ stem cell therapy derived from a patient's own blood to treat ischemic conditions including PAD, CLTI, ischemic cardiomyopathy, refractory angina, and vascular dementia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBlackfalds, Canada
HQ citystring
Blackfalds
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autologous stem cell therapy, regenerative medicine, cell therapy platform, ischemic disease treatment, clinical stage biotechnology
Industry2 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAJ
Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1ACP-01 Treatment Sales
TypeOne Time License
Description

Revenue generated from direct treatment sales at $50,000 per treatment in Florida under SB 1768, The Bahamas, and Canada. Treatment sales to no-option patients who have exhausted conventional treatments.

investors.hemostemix.com
2Therapy Convertible Debentures
TypeTransaction Fee
Description

Company sold forward $1,143,983 in Therapy Convertible Debentures year-to-date, offering investors convertible debt instruments tied to treatment revenue.

stocktitan.net
3Clinical Trial Funding
TypeProfessional Services
Description

Funding received from healthcare foundations (McGill University Health Centre Foundation) to support Phase II clinical trials, providing non-dilutive capital for research.

globenewswire.com
Marketing channels12 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Standard ACP-01 Treatment
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$50,000 per treatment for autologous stem cell therapy ACP-01 (VesCell), covering the complete treatment cycle from blood draw to cell administration.

investors.hemostemix.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Hemostemix develops and commercializes ACP-01 (marketed as VesCell), an autologous stem cell therapy derived from a patient's own blood. CD34+ angiogenic cell precursors are isolated through peripheral venipuncture, expanded over seven days in a cGMP-compliant facility, and administered via outpatient intramuscular injection to treat ischemic conditions including peripheral arterial disease, chronic limb-threatening ischemia, refractory angina, ischemic cardiomyopathy, and vascular dementia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 0% mortality in CLTI cohorts through 4.5 years follow-up vs 50% five-year mortality in untreated CLTI patients
+8 more records
Product overview1 text field

Hemostemix is a clinical-stage regenerative medicine company offering an autologous stem cell therapy platform built around ACP-01 (VesCell™), its primary product. ACP-01 is derived from a patient's own blood and evaluated for treating various ischemic and vascular conditions. The company also develops NCP-01 (Neural Cell Precursor), a complementary therapy targeting neurological applications. Both products are part of a unified platform approach where angiogenic and neural cell precursors are isolated from patient blood and processed for therapeutic use. ACP-01 has been studied across seven clinical studies involving 498 subjects, while NCP-01 represents the company's expansion into neurological indications.

Product and service2 records
1ACP-01 (VesCell)
CategoryAutologous Stem Cell Therapy
Description

Autologous stem cell therapy derived from a patient's own blood. CD34+ angiogenic cell precursors are isolated through a standard blood draw, expanded over seven days in a cGMP-compliant facility, and administered via outpatient intramuscular injection. Evaluated in clinical research for ischemic conditions including cardiovascular ischemia, peripheral arterial disease (PAD), chronic limb threatening ischemia (CLTI), and vascular dementia.

2NCP-01 (Neural Cell Precursor)
CategoryAutologous Stem Cell Therapy
Description

Neuronal cell precursor therapy derived from a patient's own blood, designed for potential applications in neurological conditions including vascular dementia and brain-computer interface research. Part of Hemostemix's broader cell therapy platform alongside ACP-01.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Dr. Desirée Cox
Strategic tierCoreTypeOthersAnnounced on2026-05-25
Description

Physician, scientist, philosopher, and bioethicist appointed to Board of Directors. Previously chaired National Stem Cell Ethics Committee in The Bahamas and spearheaded development of LARTA legislation. Founder of HEALinc global health innovation platform.

hemostemix.com
2Dr. York Hsiang
Strategic tierMinorTypeOthersAnnounced on2026-02-03
Description

Renowned vascular surgeon and former Principal Investigator appointed as Business Consultant to advance First Nations-led healthcare partnerships. Dr. Hsiang will guide joint ventures with First Nations governments for establishing treatment centers on sovereign territories, advising on clinical staffing, physician engagement, and commercialization pathways.

biospace.com
3Dominican Republic Cardiology Practices
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-26
Description

Binding Letter of Intent to acquire two cardiology practices in Dominican Republic as part of roll-up strategy. Physicians have treated over 200 patients with ACP-01. Acquisition aims to accelerate clinical and commercial presence and facilitate regulatory approvals.

newsfilecorp.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic manufacturing partnership with CytoImmune Therapeutics. $1,800,000 in financing commitments secured. BioReactor Technologies licensed for cell production.

5Dr. Nadia Giannetti, MD
Strategic tierMinorTypeOthers
Description

McGill University cardiologist appointed to Scientific Advisory Board. Former Chief of Cardiology at McGill University Health Centre (2010-2021). Co-Principal Investigator of stem cell research initiative for cardiomyopathy. Leads Courtois Cardiovascular Signature Program.

hemostemix.com
6Dr. William R. Shankle
Strategic tierMinorTypeOthers
Description

Renowned neurologist leading Phase I clinical trial of ACP-01 for treating vascular dementia. Pre-screening up to 30 vascular dementia patients from Dr. Shankle's database.

hemostemix.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mesoblast develops allogeneic mesenchymal stem cell therapies, including rexlemestrocel-L for chronic heart failure and inflammatory conditions. It is the most closely comparable late-stage cell therapy competitor targeting Hemostemix's cardiovascular and ischemic indications, with deeper capital but a longer path to US commercialization.

2Pluristem Therapeutics
TypeDirect peer
Description

Pluristem develops placenta-derived allogeneic cell therapy products (PLX-PAD) targeting peripheral artery disease and critical limb ischemia. It is a direct clinical-stage peer in the same ischemic/CLI cell therapy category as Hemostemix's ACP-01.

3Caladrius Biosciences
TypeDirect peer
Description

Caladrius has pursued autologous CD34+ cell therapy programs for CLI and other ischemic cardiovascular indications (including CLBS03), directly overlapping Hemostemix's autologous CD34+ angiogenic cell precursor approach for PAD/CLTI.

4Athersys (now Healios KK partner)
TypeDirect peer
Description

Athersys developed MultiStem, an allogeneic cell therapy platform evaluated in ischemic and inflammatory indications including stroke and cardiovascular disease. It is a comparable clinical-stage regenerative medicine peer targeting shared mechanisms of microvascular repair.

TypeDirect peer
Description

BrainStorm's NurOwn is an autologous cell therapy platform (MSC-derived neurotrophic factor-secreting cells) targeting neurodegenerative diseases. It overlaps with Hemostemix's NCP-01 (neuronal cell precursor) expansion into neurological indications such as vascular dementia.

TypeBroad incumbent
Description

Vericel commercializes autologous cell therapies (MACI for cartilage repair, Epicel for severe burns) and represents an established US commercial-stage cell therapy operator — a relevant incumbent comparable for Hemostemix's commercialization pathway in autologous therapies.

TypeBroad incumbent
Description

Lineage Cell Therapeutics develops allogeneic and autologous cell transplant therapies for CNS, oncology, and ophthalmology indications. It is a broader regenerative medicine peer with overlapping platform technology and clinical-stage pipeline structure.

8Cynata Therapeutics
TypeEmerging player
Description

Cynata is developing iPSC-derived mesenchymal stem cell products (Cymerus platform) targeting inflammatory and vascular indications. It is an emerging player with partial overlap in ischemic disease and stem-cell-derived therapeutic approaches.

TypeEmerging player
Description

Citius has pursued iMSC (induced mesenchymal stem cell) therapy for CLI and other inflammatory conditions, providing another emerging stem cell competitor in the same ischemic limb disease category as Hemostemix's CLTI program.

TypeOthers
Description

CytoImmune is both a manufacturing/strategic partner (BioReactor technology licensed to Hemostemix, $1.8M financing commitment) and a cell therapy peer. Comparable as a cell therapy infrastructure enabler and adjacent autologous/allogeneic developer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hemostemix

Cell Therapyhemostemix.com

Hemostemix is a publicly traded clinical-stage biotechnology company developing ACP-01 (VesCell), an autologous CD34+ stem cell therapy derived from a patient's own blood to treat ischemic conditions including PAD, CLTI, ischemic cardiomyopathy, refractory angina, and vascular dementia.

What Hemostemix does

Hemostemix Inc. is a clinical-stage biotechnology company headquartered in Calgary, Alberta, Canada, founded in 2003 (previously known as TheraVitae Inc.) and listed on the TSX Venture Exchange (HEM), OTCQB (HMTXF), and Frankfurt Stock Exchange (2VF0). The company develops autologous stem cell therapies for ischemic conditions that lack effective conventional treatments, with its lead product ACP-01 (marketed as VesCell) consisting of CD34+ angiogenic cell precursors isolated from a patient's own blood via peripheral venipuncture, expanded over seven days in a cGMP-compliant Montreal manufacturing facility, and administered via outpatient intramuscular injection. The platform is protected by over 90 patents across five patent families and has been evaluated across seven clinical studies involving 498 subjects, with results published in 11 peer-reviewed journals including 0% serious adverse events and 83% limb salvage in CLTI cohorts followed to 4.5 years.

The company pursues a basket IND strategy targeting six ischemic indications — peripheral arterial disease (PAD), chronic limb-threatening ischemia (CLTI), ischemic cardiomyopathy, congestive heart failure, refractory angina, and vascular dementia — all sharing microvascular perfusion insufficiency as a common mechanism. ACP-01's collection method (blood draw only) is differentiated from competitors requiring bone marrow aspiration or liposuction. The company operates a sales-led, direct-to-consumer model selling treatments at $50,000 each — well below the $300,000-$500,000 benchmarks of approved cell and gene therapies in adjacent indications. Commercial access exists in Florida under Senate Bill 1768 (Right-to-Try), The Bahamas under LARTA, and Canada through clinical frameworks, with the FDA accepting real-world evidence under IRB oversight. The company completed an FDA Pre-IND meeting in January 2026 for a basket clinical trial protocol.

Revenue mechanics rely on per-treatment cash sales plus Therapy Convertible Debentures tied to treatment revenue. Operations are funded primarily through repeated small private placements (multiple rounds in 2025-2026 totaling several million USD), insider participation by directors Mr. Lacey and Mr. Swanberg, and grant funding (e.g., $250K from McGill University Health Centre Foundation). Recent strategic moves include the appointment of Chief Commercial Officer Croom Lawrence with revenue share, a binding LOI to acquire two Dominican Republic cardiology practices in November 2025, a PreCerv Inc. spin-off housing the NCP-01 neuronal cell precursor technology, and pursuit of First Nations-led treatment center partnerships via Dr. York Hsiang.

Hemostemix firmographics

Firmographics
Name
Hemostemix
Legal name
Hemostemix Inc.
Website
https://hemostemix.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
Hemostemix is a publicly traded clinical-stage biotechnology company developing ACP-01 (VesCell), an autologous CD34+ stem cell therapy derived from a patient's own blood to treat ischemic conditions including PAD, CLTI, ischemic cardiomyopathy, refractory angina, and vascular dementia.
Ownership category
akta.pro rank

Hemostemix industry classification

Industry
Product category
Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAJ
Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Autologous stem cell therapy
  • Regenerative medicine
  • Cell therapy platform
  • Ischemic disease treatment
  • Clinical stage biotechnology

Where Hemostemix is headquartered

Location

Headquarters

HQ city
Blackfalds
HQ country
Canada
HQ region
North America

Offices4 records

Markets served

Hemostemix business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. ACP-01 Treatment Sales: Revenue generated from direct treatment sales at $50,000 per treatment in Florida under SB 1768, The Bahamas, and Canada. Treatment sales to no-option patients who have exhausted conventional treatments.
  2. Therapy Convertible Debentures: Company sold forward $1,143,983 in Therapy Convertible Debentures year-to-date, offering investors convertible debt instruments tied to treatment revenue.
  3. Clinical Trial Funding: Funding received from healthcare foundations (McGill University Health Centre Foundation) to support Phase II clinical trials, providing non-dilutive capital for research.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard ACP-01 Treatment

Go-to-market motion3 records

Distribution channels4 records

Marketing channels12 records

Hemostemix product offering

Product offering

Core offering

Hemostemix develops and commercializes ACP-01 (marketed as VesCell), an autologous stem cell therapy derived from a patient's own blood. CD34+ angiogenic cell precursors are isolated through peripheral venipuncture, expanded over seven days in a cGMP-compliant facility, and administered via outpatient intramuscular injection to treat ischemic conditions including peripheral arterial disease, chronic limb-threatening ischemia, refractory angina, ischemic cardiomyopathy, and vascular dementia.

Product overview

Hemostemix is a clinical-stage regenerative medicine company offering an autologous stem cell therapy platform built around ACP-01 (VesCell™), its primary product. ACP-01 is derived from a patient's own blood and evaluated for treating various ischemic and vascular conditions. The company also develops NCP-01 (Neural Cell Precursor), a complementary therapy targeting neurological applications. Both products are part of a unified platform approach where angiogenic and neural cell precursors are isolated from patient blood and processed for therapeutic use. ACP-01 has been studied across seven clinical studies involving 498 subjects, while NCP-01 represents the company's expansion into neurological indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • ACP-01 (VesCell) Autologous stem cell therapy derived from a patient's own blood. CD34+ angiogenic cell precursors are isolated through a standard blood draw, expanded over seven days in a cGMP-compliant facility, and administered via outpatient intramuscular injection. Evaluated in clinical research for ischemic conditions including cardiovascular ischemia, peripheral arterial disease (PAD), chronic limb threatening ischemia (CLTI), and vascular dementia.
  • NCP-01 (Neural Cell Precursor) Neuronal cell precursor therapy derived from a patient's own blood, designed for potential applications in neurological conditions including vascular dementia and brain-computer interface research. Part of Hemostemix's broader cell therapy platform alongside ACP-01.

Quantifiable outcome

  • 0% mortality in CLTI cohorts through 4.5 years follow-up vs 50% five-year mortality in untreated CLTI patients
  • +8 more outcomes

Companies that use Hemostemix

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Hemostemix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Hemostemix partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Dr. Desirée CoxcoreOthers · 25 May 2026Physician, scientist, philosopher, and bioethicist appointed to Board of Directors. Previously chaired National Stem Cell Ethics Committee in The Bahamas and spearheaded development of LARTA legislation. Founder of HEALinc global health innovation platform.
  • Dr. York HsiangminorOthers · 3 February 2026Renowned vascular surgeon and former Principal Investigator appointed as Business Consultant to advance First Nations-led healthcare partnerships. Dr. Hsiang will guide joint ventures with First Nations governments for establishing treatment centers on sovereign territories, advising on clinical staffing, physician engagement, and commercialization pathways.
  • Dominican Republic Cardiology PracticesminorStrategic or Co-development Partner · 26 November 2025Binding Letter of Intent to acquire two cardiology practices in Dominican Republic as part of roll-up strategy. Physicians have treated over 200 patients with ACP-01. Acquisition aims to accelerate clinical and commercial presence and facilitate regulatory approvals.
  • CytoImmune TherapeuticscoreStrategic or Co-development PartnerStrategic manufacturing partnership with CytoImmune Therapeutics. $1,800,000 in financing commitments secured. BioReactor Technologies licensed for cell production.
  • Dr. Nadia Giannetti, MDminorOthersMcGill University cardiologist appointed to Scientific Advisory Board. Former Chief of Cardiology at McGill University Health Centre (2010-2021). Co-Principal Investigator of stem cell research initiative for cardiomyopathy. Leads Courtois Cardiovascular Signature Program.
  • Dr. William R. ShankleminorOthersRenowned neurologist leading Phase I clinical trial of ACP-01 for treating vascular dementia. Pre-screening up to 30 vascular dementia patients from Dr. Shankle's database.

Scale indicators15 records

Recent moves8 records

Expansion highlights6 records

Hemostemix competitors and assessment

Company assessment

Direct peers

  • Mesoblast Limited: Mesoblast develops allogeneic mesenchymal stem cell therapies, including rexlemestrocel-L for chronic heart failure and inflammatory conditions. It is the most closely comparable late-stage cell therapy competitor targeting Hemostemix's cardiovascular and ischemic indications, with deeper capital but a longer path to US commercialization.
  • Pluristem Therapeutics: Pluristem develops placenta-derived allogeneic cell therapy products (PLX-PAD) targeting peripheral artery disease and critical limb ischemia. It is a direct clinical-stage peer in the same ischemic/CLI cell therapy category as Hemostemix's ACP-01.
  • Caladrius Biosciences: Caladrius has pursued autologous CD34+ cell therapy programs for CLI and other ischemic cardiovascular indications (including CLBS03), directly overlapping Hemostemix's autologous CD34+ angiogenic cell precursor approach for PAD/CLTI.
  • Athersys (now Healios KK partner): Athersys developed MultiStem, an allogeneic cell therapy platform evaluated in ischemic and inflammatory indications including stroke and cardiovascular disease. It is a comparable clinical-stage regenerative medicine peer targeting shared mechanisms of microvascular repair.
  • BrainStorm Cell Therapeutics: BrainStorm's NurOwn is an autologous cell therapy platform (MSC-derived neurotrophic factor-secreting cells) targeting neurodegenerative diseases. It overlaps with Hemostemix's NCP-01 (neuronal cell precursor) expansion into neurological indications such as vascular dementia.

Broad incumbents

  • Vericel Corporation: Vericel commercializes autologous cell therapies (MACI for cartilage repair, Epicel for severe burns) and represents an established US commercial-stage cell therapy operator — a relevant incumbent comparable for Hemostemix's commercialization pathway in autologous therapies.
  • Lineage Cell Therapeutics: Lineage Cell Therapeutics develops allogeneic and autologous cell transplant therapies for CNS, oncology, and ophthalmology indications. It is a broader regenerative medicine peer with overlapping platform technology and clinical-stage pipeline structure.

Emerging players

  • Cynata Therapeutics: Cynata is developing iPSC-derived mesenchymal stem cell products (Cymerus platform) targeting inflammatory and vascular indications. It is an emerging player with partial overlap in ischemic disease and stem-cell-derived therapeutic approaches.
  • Citius Pharmaceuticals: Citius has pursued iMSC (induced mesenchymal stem cell) therapy for CLI and other inflammatory conditions, providing another emerging stem cell competitor in the same ischemic limb disease category as Hemostemix's CLTI program.

Others

  • CytoImmune Therapeutics: CytoImmune is both a manufacturing/strategic partner (BioReactor technology licensed to Hemostemix, $1.8M financing commitment) and a cell therapy peer. Comparable as a cell therapy infrastructure enabler and adjacent autologous/allogeneic developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Hemostemix social profiles

Digital presence

Hemostemix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hemostemix leadership team

Management profile

Number of profiles

Profiles13 records

Hemostemix funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hemostemix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemostemix

What does Hemostemix do?

Hemostemix develops and commercializes ACP-01 (marketed as VesCell), an autologous stem cell therapy derived from a patient's own blood. CD34+ angiogenic cell precursors are isolated through peripheral venipuncture, expanded over seven days in a cGMP-compliant facility, and administered via outpatient intramuscular injection to treat ischemic conditions including peripheral arterial disease, chronic limb-threatening ischemia, refractory angina, ischemic cardiomyopathy, and vascular dementia.

Is Hemostemix a public or private company?

Hemostemix is a public company. It is classified as public and is currently operating.

When was Hemostemix founded?

Hemostemix was founded in 2003. It employs 11 to 50 people.

Where is Hemostemix based?

Hemostemix is headquartered in Blackfalds, Canada, in the North America region.

How does Hemostemix make money?

Three revenue lines are on record. ACP-01 Treatment Sales are the primary driver. The others are therapy Convertible Debentures and clinical Trial Funding.

Who are Hemostemix's main competitors?

Direct peers on record are Mesoblast Limited, Pluristem Therapeutics, Caladrius Biosciences, Athersys (now Healios KK partner) and BrainStorm Cell Therapeutics. Broad incumbents are Vericel Corporation and Lineage Cell Therapeutics. Emerging players are Cynata Therapeutics and Citius Pharmaceuticals. CytoImmune Therapeutics is listed as an others.

Does Hemostemix have an API?

No public API is recorded for Hemostemix.

What industry is Hemostemix in?

Hemostemix's product category is Cell Therapy. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAGAJ, Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceHemostemix Non Brokered Private PlacementHemostemix filed a Form 4B to obtain price protection for the third tranche of its non-brokered private placement, raising $1,000,000. The company expects to pay approximately $8,000 in finder fees and issue 80,000 finder warrants at $0.06 per share. Proceeds will fund sales, marketing, patient acquisition, and regulatory fees.NewsfileHemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTAHemostemix Inc. announced the commercialization of its clinical trial for VesCell™, a therapy targeting vascular dementia and cognitive impairment, with over 130 participants enrolled to date. The trial is currently pending final regulatory approvals under the Bahamas Longevity and Regenerative Therapy Act (LARTA). This development addresses a significant unmet medical need as there are currently no FDA-approved therapies for this specific condition.Stock TitanHemostemix Dementia Trial Presentation Draws 130+Hemostemix Inc. is conducting a clinical trial for VesCell™, a treatment for vascular cognitive impairment, with a presentation led by Dr. William Shankle discussing its potential benefits and the trial's details. Over 130 participants are enrolled for the presentation which highlights the urgency of addressing vascular dementia, an unmet need affecting millions globally. The clinical trial protocol is undergoing final approvals under the Bahamas Longevity and Regenerative Therapy Act (LARTA).BioSpaceHemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTAHemostemix announced a clinical trial of its VesCell autologous stem cell therapy for vascular dementia, with enrollment underway under the Bahamas LARTA. The trial evaluates safety, feasibility, and preliminary efficacy, and the company reports a case study of cognitive improvement. Final regulatory approvals are pending.NewsfileDr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical TrialHemostemix Inc. announced the appointment of Prof. Dr. Ernst von Schwarz as the Principal Investigator for its VesCell longevity clinical trial, which aims to evaluate the therapy's impact on cardiovascular health and healthy aging. The study seeks to generate evidence supporting participation in global longevity competitions with significant prize funding by measuring improvements in muscle function, cognition, and immune system markers. This development marks a strategic expansion into the health-span market, leveraging Dr. von Schwarz’s expertise in regenerative medicine.Stock TitanHemostemix Appoints von Schwarz to Lead Longevity TrialHemostemix Inc. appointed Prof. Dr. Ernst von Schwarz as the Principal Investigator for its VesCell longevity clinical trial, which aims to assess improvements in cardiovascular health, muscle function, and cognitive ability. The study is designed to generate clinical evidence supporting participation in global health-span competitions that offer significant prize funding for innovations in healthy aging.BioWorldFinancings for Aug. 3, 2026On Aug. 3, 2026, biopharma and med-tech companies including 60 Degrees, Annexon, DBV, Hemostemix, Newcelx, and Ratio raised money in public or private financings. The list is provided by BioWorld.BioSpaceHemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026Hemostemix closed the second tranche of its non-brokered private placement, raising CDN$322,250 from 6,445,000 units at CDN$0.05 each. The company also received an extension to August 14, 2026, to close the remaining $1,000,000 of the placement.NewsfileHemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026Hemostemix Inc. has closed the second tranche of its non-brokered private placement, raising CDN$322,250 through the issuance of 6,445,000 units at CDN$0.05 per unit. The TSX Venture Exchange has granted the company an extension until August 14, 2026, to close the remaining balance of the planned $1,000,000 private placement. Proceeds will be used for sales, marketing, patient acquisition, production of ACP-01 stem cell treatments, and regulatory filings with the Bahamas Ministry of Health.YahooHemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026Hemostemix Inc. closed the second tranche of its non-brokered private placement, raising aggregate gross proceeds of CDN$322,250 through the issuance of 6,445,000 units at CDN$0.05 per unit. Each unit consists of one common share and one-half of one warrant exercisable at CDN$0.12 per share for 24 months. The company intends to use the proceeds for sales, marketing, patient acquisition, and commercialization of its ACP-01 treatments, including regulatory submissions to the Bahamas Ministry of Health.